Colonial Trust Advisors Takes Position in Merck & Co. (MRK)

Colonial Trust Advisors acquired a new position in shares of Merck & Co. (NYSE:MRK) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 6,585 shares of the company’s stock, valued at approximately $371,000.

Other hedge funds have also recently modified their holdings of the company. Santori & Peters Inc. acquired a new position in Merck & Co. during the fourth quarter worth $110,000. Stevens First Principles Investment Advisors raised its holdings in Merck & Co. by 79.3% during the fourth quarter. Stevens First Principles Investment Advisors now owns 2,080 shares of the company’s stock worth $117,000 after purchasing an additional 920 shares during the last quarter. Avestar Capital LLC purchased a new position in Merck & Co. during the fourth quarter worth $130,000. WealthTrust Arizona LLC increased its position in Merck & Co. by 103.7% during the fourth quarter. WealthTrust Arizona LLC now owns 2,495 shares of the company’s stock worth $140,000 after buying an additional 1,270 shares in the last quarter. Finally, Taylor Hoffman Wealth Management purchased a new position in Merck & Co. during the fourth quarter worth $156,000. 74.87% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts have weighed in on the company. Jefferies Group set a $55.00 price target on Merck & Co. and gave the stock a “hold” rating in a research report on Friday, March 23rd. ValuEngine downgraded Merck & Co. from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. DZ Bank raised Merck & Co. from a “hold” rating to a “buy” rating in a research report on Tuesday, February 13th. Morgan Stanley raised their price target on Merck & Co. from $60.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. Finally, Credit Suisse Group dropped their price target on Merck & Co. from $67.00 to $66.00 and set an “outperform” rating for the company in a research report on Monday, February 5th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $65.87.

Shares of NYSE:MRK opened at $59.07 on Friday. The firm has a market capitalization of $159.61 billion, a PE ratio of 14.84, a price-to-earnings-growth ratio of 2.25 and a beta of 0.76. The company has a quick ratio of 1.10, a current ratio of 1.42 and a debt-to-equity ratio of 0.63. Merck & Co. has a 52 week low of $59.04 and a 52 week high of $59.65.

Merck & Co. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, May 1st. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $1.00 by $0.05. The business had revenue of $10.04 billion during the quarter, compared to the consensus estimate of $10.09 billion. Merck & Co. had a return on equity of 30.93% and a net margin of 4.31%. The business’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.88 earnings per share. research analysts anticipate that Merck & Co. will post 4.23 earnings per share for the current fiscal year.

In other news, insider Weir Mirian M. Graddick sold 24,000 shares of Merck & Co. stock in a transaction on Monday, April 16th. The stock was sold at an average price of $58.00, for a total value of $1,392,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Julie L. Gerberding sold 9,972 shares of Merck & Co. stock in a transaction on Tuesday, May 15th. The shares were sold at an average price of $59.66, for a total value of $594,929.52. The disclosure for this sale can be found here. 0.32% of the stock is owned by insiders.

About Merck & Co.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit